Compare Stocks

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$2.16 -6.9%	$1.61	$0.76 ▼ $14.00	$8.75M	1.48	5.35 million shs	130,365 shs
RGLS Regulus Therapeutics	$2.19 -6.4%	$2.10	$1.08 ▼ $3.79	$143.37M	1.57	2.58 million shs	147,630 shs
SXTC China SXT Pharmaceuticals	$0.98 -17.4%	$1.82	$0.94 ▼ $9.38	$448K	1	1.06 million shs	1.23 million shs
UMRX Cogent Biosciences	$6.53 +1.1%	$10.50	$0.29 ▼ $3.72	$277.32M	3.93	1.22 million shs	2.01 million shs
VVUS VIVUS		$0.37	$0.44 ▼ $4.75	$7.33M	-0.84	1.44 million shs	2.03 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	+3.57%	-0.43%	+42.33%	+78.28%	-69.79%
RGLS Regulus Therapeutics	-8.59%	-10.69%	-0.85%	+91.80%	+90.24%
SXTC China SXT Pharmaceuticals	-27.16%	-28.48%	-29.34%	-32.95%	-80.33%
UMRX Cogent Biosciences	+1.08%	-1.80%	-3.12%	+33.81%	-41.17%
VVUS VIVUS	0.00%	0.00%	0.00%	0.00%	0.00%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	2.7719 of 5 stars	4.4	2.0	0.0	0.0	2.7	2.5	0.0
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	2.80	Moderate Buy	$7.25	231.05% Upside
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest UMRX, RGLS, SXTC, VVUS, and ADIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/25/2024	RGLS Regulus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
3/19/2024	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
3/18/2024	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/18/2024	RGLS Regulus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
3/18/2024	RGLS Regulus Therapeutics	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
3/13/2024	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $3.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$2.46 per share	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.05 per share	N/A
SXTC China SXT Pharmaceuticals	$1.97M	0.23	N/A	N/A	$32.12 per share	0.03
UMRX Cogent Biosciences	$22.50M	12.33	N/A	N/A	$1.04 per share	6.28
VVUS VIVUS	$69.76M	0.00	N/A	N/A	($6.50) per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$5.12M	-$5.72	N/A	N/A	N/A	N/A	-250.52%	-183.24%	5/10/2024 (Estimated)
RGLS Regulus Therapeutics	-$30.04M	-$1.59	N/A	N/A	N/A	N/A	-109.21%	-80.55%	5/9/2024 (Estimated)
SXTC China SXT Pharmaceuticals	-$5.93M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/29/2024 (Estimated)
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A
VVUS VIVUS	-$31.50M	-$2.96	N/A	N/A	N/A	-39.28%	N/A	-12.18%	N/A

Latest UMRX, RGLS, SXTC, VVUS, and ADIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	RGLS Regulus Therapeutics	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	4.90	4.90
RGLS Regulus Therapeutics	N/A	3.31	3.31
SXTC China SXT Pharmaceuticals	0.02	1.47	1.41
UMRX Cogent Biosciences	0.18	2.90	2.90
VVUS VIVUS	N/A	0.43	0.28

Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
RGLS Regulus Therapeutics	92.38%
SXTC China SXT Pharmaceuticals	5.02%
UMRX Cogent Biosciences	26.39%
VVUS VIVUS	7.32%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	14.47%
RGLS Regulus Therapeutics	8.41%
SXTC China SXT Pharmaceuticals	3.95%
UMRX Cogent Biosciences	31.50%
VVUS VIVUS	12.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	16	4.05 million	3.47 million	No Data
RGLS Regulus Therapeutics	30	65.47 million	59.96 million	Optionable
SXTC China SXT Pharmaceuticals	78	460,000	439,000	Not Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable
VVUS VIVUS	57	17.87 million	N/A	Optionable

UMRX, RGLS, SXTC, VVUS, and ADIL Headlines

Source	Headline
	VIVUS Provides Update on Pipeline and Program Milestones markets.businessinsider.com - January 8 at 10:04 AM
	Shark research group to build new global headquarters in Jacksonville with help from state funding actionnewsjax.com - June 26 at 9:16 AM
	Metaview announces Answers, the world's first conversational AI for the interview process it.tmcnet.com - May 25 at 11:10 AM
	Pancrelipase (CAS 53608-75-6) Market 2023 \| Industry Growth ... - StreetBuzz news.google.com - May 12 at 2:58 AM
	Exploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital Journal news.google.com - May 12 at 2:58 AM
	Extensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPR news.google.com - May 11 at 8:54 AM
	Erectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay Journal news.google.com - May 11 at 8:54 AM
	Milestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR Newswire news.google.com - May 11 at 8:54 AM
	Anti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay Journal news.google.com - May 11 at 3:54 AM
	Anti Obesity Drugs Market Future Industry Scope for New ... - Digital Journal news.google.com - May 11 at 3:54 AM
	This Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolution news.google.com - May 10 at 12:51 PM
	Prostatic Artery Embolization Market Current and Upcoming Projects ... - Digital Journal news.google.com - May 9 at 6:48 AM
	This 1899 Porsche Pioneered Rivian's Quad-Motor Drive, Ram ... - MotorBiscuit news.google.com - May 7 at 8:20 PM
	Porsche Pioneered the Range-Extended EV 100+ Years Before ... - MotorBiscuit news.google.com - May 6 at 3:22 PM
	Increasing Opportunities In Peripherally Acting Anti-Obesity Drug Market Latest Trends, Technological Advancem - openPR news.google.com - May 5 at 1:45 PM
	Nonalcoholic Steatohepatitis Treatment Market Outlook Growths ... - Digital Journal news.google.com - May 5 at 7:44 AM
	A Big Fat Problem: Will children in the UK be given weight-loss injections? - Firstpost news.google.com - May 2 at 10:24 AM
	Intraoperative Ultrasound Market Latest Trends, Techniques and Applications\|2023-2030 - openPR news.google.com - April 28 at 9:38 AM
	Build Your Own Case Study \| Obesity: Treating the Whole Patient - Healio news.google.com - April 27 at 8:14 PM
	Bladder Cancer Market Demand in Various industries and Significant for Various Regions\|2023-2030 - openPR news.google.com - April 27 at 3:10 PM
	Pediatric Obesity Management Market is projected to grow with a 4 ... - Future Market Insights news.google.com - April 27 at 10:10 AM
	Global Erectile Dysfunction Drugs Market Analysis by Recent Trends, Development, Regional Growth Overview and - openPR news.google.com - April 26 at 7:33 AM
	Non-Alcoholic Steatohepatitis (NASH) Market Analysis, Trends, Growth, Research And Forecast 2032 - openPR news.google.com - April 25 at 2:02 AM
	What to Know About Obesity and Bone Health - Health Central news.google.com - April 24 at 4:02 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adial Pharmaceuticals

NASDAQ:ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Regulus Therapeutics

NASDAQ:RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

China SXT Pharmaceuticals

NASDAQ:SXTC

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Cogent Biosciences

NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

VIVUS

NASDAQ:VVUS

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial